Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$4.91 USD
+0.04 (0.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUPH 4.91 +0.04(0.82%)
Will AUPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
Other News for AUPH
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals to Present at Investor Conference
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Aurinia Pharmaceuticals Announces Q1 Results Date